IMCD updates its analyst consensus picture, shares tracked against European peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 13:37.

IMCD (NL0010801007) enters midweek with a defined analyst consensus and a stable role among European specialty chemicals distributors such as Brenntag. Recent analyst overviews from platforms like MarketScreener underline how the stock is currently rated and where earnings expectations cluster.

How analysts currently rate IMCD

According to the latest analyst summary on MarketScreener, IMCD is covered by a double-digit number of research houses, with a majority of ratings in the Buy or Outperform range and a smaller group recommending Hold based on valuation and execution risk. The consensus target price in that overview stands clearly above the current quotation, implying measurable upside on a 12-month view, even if individual houses have trimmed their targets after the last results update, as the MarketScreener consensus page for IMCD shows MarketScreener consensus data.

Several large banks such as ING and ABN AMRO, alongside international brokers, remain in coverage and focus on IMCD's acquisitive growth model, balance sheet discipline and exposure to higher-margin specialty ingredients. Their notes highlight that cash generation and integration of past deals are key for further rating stability, while any slowdown in European industrial demand could lead to estimate revisions, as reflected in recent commentary collated by financial portals that track broker recommendations on the stock finanzen.net analyst overview.

Consensus estimates and peer comparison

In terms of numbers, MarketScreener cites a current consensus for IMCD's 2026 revenue and EBITDA that assumes mid to high single-digit organic growth, complemented by bolt-on acquisitions. That would keep the EBITDA margin broadly stable versus recent years, a pattern similar to distributor peer Brenntag, where analysts likewise expect modest margin expansion after cost optimizations, according to the broker tables for the German group on MarketScreener Brenntag consensus comparison.

Valuation-wise, consensus tables show IMCD trading at a forward earnings multiple in the high teens, above many traditional chemical producers but more in line with asset-light distribution peers that deliver structurally higher returns on capital. Analysts point out that this premium is conditional on continued disciplined acquisition activity and stable cash conversion, as summarized in recent comments on the stock from European broker round-ups that emphasize free-cash-flow yields and leverage metrics as key watchpoints for investors following the Amsterdam listing Investing.com estimates overview.

How IMCD makes its money

IMCD operates as a global distributor of specialty chemicals and ingredients, connecting producers with industrial and consumer end markets through technical sales teams and application laboratories. In areas such as food and nutrition, IMCD supplies functional ingredients for processed foods, beverages and dietary products, helping brand owners and manufacturers to formulate new recipes and adapt to regulatory changes.

Where the IMCD shares trade today

The IMCD shares (NL0010801007) trade on Euronext Amsterdam; the most recently verifiable quotation on the exchange shows the stock in euros with a market capitalization in the multi-billion range on the latest available trading day.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any financial instrument. All data is based on sources believed to be reliable but cannot be guaranteed.